Intrathecal cyclodextrin in the treatment of Niemann-Pick disease type C

Area of Science:

• Neurology
• Genetics
• Pharmacology

Background:

• Niemann-Pick disease type C (NPC) is a rare genetic disorder affecting lipid metabolism.
• Current therapeutic options for NPC are limited, necessitating research into novel treatments.

Purpose of the Study:

• To evaluate the safety and efficacy of intrathecal hydroxypropyl-β-cyclodextrin in a child with Niemann-Pick disease type C.
• To assess the therapeutic potential of this novel drug delivery method for NPC.

Main Methods:

• A pediatric patient diagnosed with Niemann-Pick disease type C initiated miglustat therapy.
• Intrathecal hydroxypropyl-β-cyclodextrin was administered, with dosage escalation over six months.
• The patient received 43 doses every 15 days.

Main Results:

• A temporary, slight delay in disease progression was observed during the first year of treatment.
• The emergence of additional symptoms suggests limited long-term effectiveness of the therapy.
• No drug-related adverse events were reported, indicating a favorable safety profile.

Conclusions:

• Intrathecal hydroxypropyl-β-cyclodextrin demonstrates a good safety profile in this NPC patient.
• The therapeutic efficacy of intrathecal hydroxypropyl-β-cyclodextrin appears questionable for the severe infantile form of Niemann-Pick disease type C.